Addressing Waste and Fraud in Government Health Programs
Brian Blase, President of Paragon Health Institute and former Special Assistant for Economic Policy in the White House's National Economic Council from 2017 to 2019, is spearheading an event on April 28 at the National Press Club. This event will tackle issues of improper payments, waste, and fraud within government health programs. Esteemed speakers such as Dr. Oz, Sen. Ron Johnson, and Rep. John Joyce are set to contribute to the discourse.
Federal health program spending is under scrutiny due to extensive waste, fraud, and abuse, particularly within Medicaid and the ACA exchanges. Recent data points to over $100 billion in annual federal Medicaid expenditures potentially being improper. Despite persistent challenges, the focus remains on addressing these inefficiencies to streamline health service delivery.
In 2024, the Centers for Medicare and Medicaid Services noted that national health expenditures hit a staggering $5.3 trillion, accounting for 18% of GDP. Of this figure, federal health spending made up $1.7 trillion, largely driven by policies surrounding employer-provided insurance and the ACA. These factors collectively influence surging health care prices.
The Paragon Policy Information Center (PIC) indicates that by 2025, health care spending will represent approximately 62% of federal income taxes, reflecting a significant climb from previous years. Medicare costs, partially covered by payroll taxes, rely heavily on general revenues for Parts B and D. The continuous climb in Medicaid and ACA subsidy allocations compounds budgetary pressures.
The Paragon PIC reports a rise in ACA enrollees claiming income within the 100 to 150% federal poverty level bracket, leading to increased subsidies for insurers. These improper enrollments, exacerbated by COVID-era subsidy expansions, highlight the presence of phantom enrollees within the exchanges, straining fiscal resources.
On April 16, Ryan Long from Paragon will testify before the Senate HELP Committee, focusing on prescription drug costs. He will emphasize the profound savings, over $3 trillion to date, garnered from generics and biosimilars. Long plans to propose regulatory updates and incentives to dismantle rebate systems that hinder low-cost drug access, promoting wider adoption of affordable alternatives.
In a separate event, Paragon recently hosted a virtual discussion evaluating smartphone policies in schools, shedding light on improved classroom dynamics when usage is restricted. Insights from lawmakers and educators reinforced the positive outcomes associated with stringent usage regulations.
Stay informed on the latest in health policy by following Paragon Health Institute's publications.